Vivek Makwana

Vivek Makwana

Auto-generated profile, based on publicly available information

Vivek Makwana

School of Pharmacy and Pharmacology, Griffith University, Gold Coast, Queensland 4222, Australia

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2015 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
VMVivek Makwana
Vivek Makwana
RJRashmi Jain
Rashmi Jain
KPKomal Patel
Komal Patel
MNManish Nivsarkar
Manish Nivsarkar
AJAmita Joshi
Amita Joshi

21 May 2018 in ACS Chemical Neuroscience
Verified
Journal Article
Closed access
PRPhilip Ryan
Philip Ryan
BPBhautikkumar Patel
Bhautikkumar Patel
VMVivek Makwana
Vivek Makwana
HJHemant R. Jadhav
Hemant R. Jadhav
MKMilton John Kiefel
Milton John Kiefel
MKMichael Kassiou
Michael Kassiou

1 August 2019 in Biochimica et Biophysica Acta (BBA) - General Subjects
Verified
Journal Article
Closed access
VMVivek Makwana
Vivek Makwana
PRPhilip Ryan
Philip Ryan
BPBhautikkumar Patel
Bhautikkumar Patel
SAShailendra Anoopkumar-Dukie
Shailendra Anoopkumar-Dukie
SRSantosh Rudrawar
Santosh Rudrawar

1 June 2019 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
BPBhautikkumar Patel
Bhautikkumar Patel
PRPhilip Ryan
Philip Ryan
VMVivek Makwana
Vivek Makwana
MZMatthew Zunk
Matthew Zunk
SRSantosh Rudrawar
Santosh Rudrawar
GGGary Grant
Gary Grant

27 August 2020 in International Journal of Toxicology
Verified
Journal Article
Open access
PDF file
VMVivek Makwana
Vivek Makwana
ADA/Prof Shailendra-Anoopkumar Dukie
A/Prof Shailendra-Anoopkumar Dukie
SRSantosh Rudrawar
Santosh Rudrawar
Reduction in sensitivity in terms of cytotoxicity is responsible for therapy failure in patients undergoing chemotherapy with first-line anticancer drug molecules. A plethora of literature evidence points out that increased O-linked β-N-acetylglucosamine transferase (OGT) enzyme level/hyper-O-GlcNAcylation has direct implications in development of cancer and interferes with clinical outcomes of chemotherapy via interaction with oncogenic factors. The aim of this research was to evaluate the combination approach of anticancer drugs with an OGT inhibitor (OSMI-1) as an alternative way to resolve issues in the treatment of prostate cancer and assess the benefits offered by this approach. Effect of combination of doxorubicin and docetaxel with OSMI-1 on drug-induced cell death and synergism/antagonism was investigated using resazurin assay. Reduction in OGT enzyme level was evaluated using ELISA kit. Caspase-3/7 fluorescence assay was performed to detect apoptosis induction in PC-3 cells after treatment with the combinations of doxorubicin and OGT inhibitor to further understand the mechanism of cell death by concomitant treatment. Studies reveal that combination approach is indeed effective in terms of reducing the half-maximum growth inhibition value of doxorubicin when concomitantly treated with OSMI-1 and has synergistic effect in prostate cancer cells. PC-3 cells exhibited elevated levels of OGT enzyme in comparison to WPMY-1, and OSMI-1 has potential to inhibit OGT enzyme significantly. Data show that OSMI-1 alone and in combination with doxorubicin reduces OGT enzyme level significantly accompanied by increased apoptosis in prostate cancer cells. Combination of doxorubicin with OSMI-1 reduced the elevated OGT level which led to a drastic increase in sensitivity of PC-3 cells toward doxorubicin in comparison to doxorubicin alone. This finding provides important insight regarding alternative treatment strategies for effective management of cancer.

21 August 2020 in Australian Journal of Chemistry
Verified
Journal Article
Closed access
PDF file
LRLuke P. Robertson
Luke P. Robertson
VMVivek Makwana
Vivek Makwana
TVTanja M. Voser
Tanja M. Voser
DHDarren C. Holland
Darren C. Holland
ACAnthony Carroll
Anthony Carroll
One new furoquinoline alkaloid, leptanoine D (1) and nine known alkaloids 2–10 were isolated from Pitaviaster haplophyllus. Leptanoine D (1) contains a typically unstable vinyl ether moiety and was structurally elucidated based on 2D NMR, (+)-HR-ESI-MS, and ECD data. The structures of the known furoquinoline alkaloids leptanoine A (11) and B (12) have also been revised. Compounds 1–10 were screened against three species of bacteria (Staphylococcus aureus, Pseudomonas aeruginosa, and Escherichia coli), however they showed no activity at the highest dose tested (32 µg mL−1). The compounds were also evaluated for anti-proliferative action against PC-3 and WPMY-1 cells, with 7–9 displaying weak activity at 100 μM.